Raddeanin A (RA) Inhibited EMT and Stemness in Glioblastoma via downregulating Skp2

Scientists elucidated Raddeanin A’s significant antitumor efficacy against glioblastoma in vitro and in vivo by targeting pathways linked to stemness and epithelial-mesenchymal transition, chiefly via the downregulation of S phase kinase-associated protein 2 (Skp2).